Bonaventure Equity, LLC

I'm very proud of the work we do at Bonaventure Equity, LLC. We're a collaboration of partners, founders, and researchers tackling healthcare’s biggest challenges. We consider ourselves to be one of the leading investors in very early stage developments and advancement of controlled substances. What that means for us is we believe we're on an entirely new paradigm with an opportunity to develop a whole new class of small molecules for treating healthcare's biggest needs. And that encapsulated in controlled substances is a treasure trove of assets that are proving with early science, early research to be highly efficacious and really profoundly valid. The clip below is from our recent webinar on FDA & The Collapose of Lykos | The Opportunity for Psychedelics. You can watch the full webinar here: https://lnkd.in/eDG6BRd6 #Webinar #LykosCollapse #Opportunity #

With the recent headlines touting the FDA rejection of Lykos (MAPS), MDMA treatment application as a major blow to psychedelics and now the announcement that the company has cut 75% of its staff, you'd think investors would be running?for the hills.? In fact the opposite is true, so join us for an informative webinar to expand on how this is actually a net benefit to the advancement?of psychedelic treatments.

?? **News from FloraWorks!** ?? We are thrilled to announce the appointment of Matthew Roberts, Ph.D., MBA as our new Chief Operating Officer. With over 25 years of experience in the health and wellness sectors, Dr. Roberts brings a wealth of knowledge and expertise to our team. His impressive background with industry leaders such as Pharmavite, The Nature's Bounty Co. , Abbott Nutrition NL, and Nestlé positions him perfectly to drive FloraWorks' next phase of growth and innovation. As we enter into the nutraceutical cannabinoid ingredient space with TruCBN, our clinically validated CBN isolate, we are poised to revolutionize how people experience cannabinoids. With Dr. Roberts' leadership, we are confident that FloraWorks will elevate TruCBN to new heights, ensuring its success and mainstream adoption. Matthew Roberts, Ph.D., MBA welcome to the FloraWorks team! We look forward to his strategic insights and operational excellence propelling our mission to advance cannabinoid therapeutics. #FloraWorks #Leadership #CannabinoidTherapeutics #TruCBN #Innovation #Growth #HealthAndWellness https://lnkd.in/ekWBurYE

Bonaventure Equity is proud to welcome Psilera to the BVE Fund II portfolio. This innovative biotechnology firm is advancing the field of psychedelic-based treatments with a robust pipeline that includes four distinct drug candidates, highlighted by a leading therapy for Frontotemporal Dementia and related symptomatology. Psilera stands out as a pioneering early-stage company, driven by a team of PhDs who lead in developing next-generation solutions for challenging neurological disorders. With 13 issued and pending patents, Psilera exemplifies the type of high-quality, innovative ventures Bonaventure Equity targets for investment. https://lnkd.in/gDTNU4bg Psilera Bonaventure Equity, LLC Ross O'Brien

Did you know that rescheduling?of cannabis is reshaping the future of healthcare? Join us June 11 to learn about: ??Our investment thesis, portfolio, and opportunities. ??The scientific advancements and research potential being driven now that rescheduling is happening. ??What's actually happening in DC. ??How you can best position yourself as an investor in the current landscape.